Xeljanz (Tofacitinib) for Rheumatoid Arthritis

Overview
- Usage: Xeljanz is prescribed for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
- Mechanism: It is an immunomodulator and a disease-modifying antirheumatic drug (DMARD) that works Show Full Answer

Xeljanz (Tofacitinib) for Rheumatoid Arthritis

Overview:
- Usage: Xeljanz is prescribed for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
- Mechanism: It is an immunomodulator and a disease-modifying antirheumatic drug (DMARD) that works by inhibiting Janus kinases, which are involved in signaling the immune system to attack the body’s connective tissues.
- Administration: Taken orally as a tablet once or twice daily.

Common Side Effects:
- Diarrhea
- Headache
- Respiratory tract infections
- Common cold
- Urinary tract infections

Serious Side Effects:
- Blood clots (deep vein thrombosis, pulmonary embolism)
- Serious infections
- Lymphoma and other cancers

Safety Concerns:
- Recent studies have raised concerns about heart and cancer risks.
- The FDA has a boxed warning for blood clots, infection, and certain cancers.
- Ongoing research is needed to understand additional risks.

FDA Recommendations:
- Patients should not stop taking Xeljanz without consulting their provider.
- Providers should weigh the benefits and risks when prescribing or continuing the medication.

Cimzia (Certolizumab Pegol) for Rheumatoid Arthritis

Note: Specific details about Cimzia were not provided in the context. For more information, please consult a healthcare provider or a reliable medical source.

If you have any specific questions or concerns about these treatments, it's best to discuss them with your healthcare provider.

 This AI-generated response comes from myRAteam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Xeljanz Study Raises Some Concerns About Heart and Cancer Risks: What Patients Need to Know

Xeljanz (Tofacitinib) for Rheumatoid Arthritis | myRAteam